A MOLECULAR-BASED APPROACH TO INVESTIGATE BREAST CANCER 1 AND BREAST CANCER 2 STATUS IN OVARIAN CANCER AMONG IRAQI WOMEN

Muhannad Shweash; Saddam Jumaa Naseer; Maisam Khider Al-anii; Thulfiqar Fawwaz Mutar

doi:10.22159/ajpcr.2018.v11i7.25217

Authors

Muhannad Shweash Department of Clinical Laboratories Sciences, College of Pharmacy, University of Anbar, Anbar, Ramadi, Iraq.
Saddam Jumaa Naseer Department of Pharmaceutics, College of Pharmacy, University of Anbar, Anbar, Ramadi, Iraq.
Maisam Khider Al-anii Department of Basic Sciences, College of Dentistry,University of Anbar, Anbar, Ramadi, Iraq.
Thulfiqar Fawwaz Mutar Department of Environmental Studies, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i7.25217

Keywords:

Breast cancer 1, Breast cancer 2, Mutation, Ovarian cancer, Polymerase chain reaction

Abstract

Objective: Cancer ovary is one of the fatal gynecologic malignancies worldwide. Since breast cancer (BRCA) genes are considered tumor suppressor genes and play important roles in cancer by repairing of chromosomal damage with the error repair of DNA breaks. Therefore, breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) gene mutations strongly enhance the development of ovarian cancer risk among women. Here, we report that both genes are an essential mediator of progress ovarian cancer, to determine the influence of BRCA1 and BRCA2 mutations in the improvement of ovarian cancer.

Methods: A total of 25 subjects were chosen for the genetic studies, and three groups were recruited: fifteen ovarian cancer patients group, five healthy controls, and five first-degree relatives to a known case of ovarian cancer patients.

Results: A genetic analysis revealed that a strong correlation exists between both gene mutations' status in ovarian cancer, and BRCA gene mutations (185delAG, 5382insC, and 4153delA in BRCA1 and 6174delT in BRCA2) remained to establish to have a relatively high frequency among people in this study among ovarian cancer patients. Furthermore, seven patients with ovarian cancer carried all of the four investigated mutations, and five had three mutations.

Conclusion: Otherwise, BRCA gene frequency showed low prevalence among first-degree relatives, and to a lesser extent among healthy controls, with only a few had all of the mutations combined. These data demonstrate for the first time a molecular link between BRCA1 and BRCA2 mutations in ovarian cancer progression in Iraq.

Downloads

Download data is not yet available.

Author Biography

Muhannad Shweash, Department of Clinical Laboratories Sciences, College of Pharmacy, University of Anbar, Anbar, Ramadi, Iraq.

Department of Clinical Laboratories Sciences

References

Estanqueiro M, Amaral MH, ConceiÃ§Ã£o J, Lobo JM. Evolution of liposomal carriers intended to anticancer drug delivery: An overview. Int J Curr Pharm Res 2015;6:3-10.

Chen Y, Lee WH, Chew HK. Emerging roles of BRCA1 in transcriptional regulation and DNA repair. J Cell Physiol 1999;181:385-92.

Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12- 13. Science 1994;265:2088-90.

King MC. Late-Breaking Research Session. Canada: American Society of Human Genetics Annual Meeting. Montreal Quebec; 1994.

Somasundaram K. Breast cancer gene 1 (BRCA1): Role in cell cycle regulation and DNA repair-perhaps through transcription. J Cell Biochem 2003;88:1084-91.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.

King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643 6.

El-Harith EA, Abdel-Hadi MS, Doerk T, Badr AN, Schmidtke J. The potential benefits of genetic testing in breast and ovarian cancer. Saudi Med J 1999;20:663-70.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in ashkenazi jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-81.

Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Gen 1998;63:45-51.

Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol 2004;159:319-35.

Iyer P, Kumar S, Karthikeyan S, Namboori PK. â€˜BRCA1â€™ responsiveness towards breast cancer-a population-wise pharmacogenomic analysis. Int J Pharm Pharm Sci 2016;8:267-70.

Taneja N, Kukal S, Mani S. Cytb: A hot spot for pathogenic mutations in mitochondrial genome of breast cancer and ovarian cancer patients. Int J Pharm Pharm Sci 2015;7:128-35.

Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, et al. Identification of germline 185delAG BRCA1 mutations in non- Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 2003;98:597-602.

Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, et al. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 2006;119:2832-9.

Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Prev Biomarkers 2005;14:1666-71.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. AmJ Hum Genet 2001;68:700-10.

Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, et al. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 1998;7:801-5.

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.

Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Hum Mutation 1999;14:92-96.

Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 1997;60:1239-42.

Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer 2005;4:77-84.

Sobczak K, KozÅ‚owski P, NapieraÅ‚a M, Czarny J, WoÅºniak M,KapuÅ›ciÅ„ska M, et al. Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland. Oncogene 1997;15:1773-9.

Elsakov P, Kurtinaitis J, Petraitis S, Ostapenko V, Razumas M, Razumas T, et al. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. Clin Genet 2010;78:373-6.

Menkiszak J, Gronwald J, GÃ³rski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106:942-5.

Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.

Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.

Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002;346:1660-2.